21 results on '"Leon, Kalet"'
Search Results
2. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: A versatile platform for fine epitope mapping
3. Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1.
4. Immunological self-tolerance: Lessons from mathematical modeling
5. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells
6. Differential Effects of IL2Rα and IL15Rα over the Stability of the Common Beta-Gamma Signaling Subunits of the IL2 and IL15 Receptors.
7. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
8. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
9. Computational proteomics pitfalls and challenges: HavanaBioinfo 2012 Workshop report
10. Characterizing steady states of genome-scale metabolic networks in continuous cell cultures.
11. Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
12. Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
13. Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform.
14. Mathematical Models of the impact of IL2 modulation therapies on T cell dynamics.
15. Therapeutic Approaches to Target Cancer Stem Cells.
16. How regulatory CD25+CD4+T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors
17. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells.
18. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
19. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
20. Modulation of CD4 T cell function via CD6-targeting.
21. How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.